A Randomized Controlled Trial of Exercise Training Among Men With Type 2-diabetes
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00666094|
Recruitment Status : Completed
First Posted : April 24, 2008
Last Update Posted : February 9, 2017
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus, Type 2 Hyperglycemia||Behavioral: Endurance training Behavioral: strength training|
Exercise training is well documented as part of effective treatment for type 2-diabetes patients. Endurance training has been suggested as the most suitable form of exercise. There are reasons to believe that strength training also has a positive effect. However, comparisons of endurance training and strength training regimes are limited.
Therefore we randomized 26 men with type 2-diabetes to either an endurance training group or a strength training group. Both groups exercised three sessions per week for three months. The training was supervised.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||26 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Randomized Controlled Trial of Strength Versus Aerobic Exercise Training to Improve Glycemic Control in Men With Type 2-diabetes|
|Actual Study Start Date :||August 2008|
|Primary Completion Date :||March 2010|
|Study Completion Date :||March 2010|
Active Comparator: endurance training
supervised endurance training
Behavioral: Endurance training
supervised endurance training. Three sessions per week in three months.
Other Name: Aerobic training
Experimental: strength training
Supervised strength training
Behavioral: strength training
Supervised strength training. Three sessions per week in three months.
- HbA1C [ Time Frame: 12.01.08 ]
- body composition, C-peptid, BP, Cholesterol (LDL, HDL), Triglycerides [ Time Frame: 12.01.08 ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00666094
|Study Director:||Liv B Augestad, PhD||NTNU|